COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00640419
Recruitment Status : Completed
First Posted : March 21, 2008
Last Update Posted : January 18, 2013
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )

Brief Summary:
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).

Condition or disease Intervention/treatment Phase
Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/Day and 1.4 mg/kg/Day of ABT-089 in the Treatment of Children With Attention Deficit-Hyperactivity Disorder (ADHD)
Study Start Date : March 2008
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: ABT-089
Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.

Experimental: 2 Drug: ABT-089
Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.

Placebo Comparator: 3 Drug: placebo
Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.

Primary Outcome Measures :
  1. ADHD-RS-IV (HV) [ Time Frame: Screening, Day -1, Day 7, Day 14, Day 28, Day 42 ]

Secondary Outcome Measures :
  1. CSHQ [ Time Frame: Day-1, Day 28, Day 42 ]
  2. CGI-P [ Time Frame: Day -1, Day 21, Day 42 ]
  3. BRIEF [ Time Frame: Day -1, Day 28, Day 42 ]
  4. CGI-ADHD-S [ Time Frame: Screening, Day -1, Day 7, Day 14, Day 28 and Day 42 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have voluntarily signed an informed consent form.
  • Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with parent(s).
  • Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG.
  • Subject weights at least 37 pounds (17 kg)
  • Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.
  • Subject can swallow pills and subjects and parents are able to keep required appointments for clinic visits and all tests, including blood draws and examinations.

Exclusion Criteria:

  • Subject has a current or past diagnosis of bipolar disorder, psychosis, autism, Asperger syndrome, pervasive developmental disorder, tics, Tourette syndrome, mental retardation, seizure disorder or traumatic brain injury.
  • Current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder or depressive disorder requiring treatment of any kind.
  • Subject has a history of, or ongoing, serious medical problem.
  • Subject has a history of significant allergic reaction to any drug.
  • Subject is planning to begin any type of behavioral or psychotherapy for treatment of ADHD.
  • Subject requires ongoing treatment with any psychiatric medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00640419

Layout table for location information
United States, Arkansas
Site Reference ID/Investigator# 7536
Little Rock, Arkansas, United States, 72205
United States, Florida
Site Reference ID/Investigator# 7954
Bradenton, Florida, United States, 34208
Site Reference ID/Investigator# 7543
Jacksonville, Florida, United States, 32216
Site Reference ID/Investigator# 7542
Orlando, Florida, United States, 32806
United States, Illinois
Site Reference ID/Investigator# 7537
Libertyville, Illinois, United States, 60048
United States, Kansas
Site Reference ID/Investigator# 7561
Overland Park, Kansas, United States, 66212
United States, Michigan
Site Reference ID/Investigator# 7560
Troy, Michigan, United States, 48085
United States, Nebraska
Site Reference ID/Investigator# 7559
Omaha, Nebraska, United States, 68198
United States, Nevada
Site Reference ID/Investigator# 7541
Las Vegas, Nevada, United States, 89128
United States, Oklahoma
Site Reference ID/Investigator# 7564
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
Site Reference ID/Investigator# 7538
Portland, Oregon, United States, 97210
United States, Tennessee
Site Reference ID/Investigator# 7540
Memphis, Tennessee, United States, 38119
United States, Washington
Site Reference ID/Investigator# 7544
Bellevue, Washington, United States, 98007
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Layout table for investigator information
Study Director: Laura Gault AbbVie
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT00640419    
Other Study ID Numbers: M10-345
First Posted: March 21, 2008    Key Record Dates
Last Update Posted: January 18, 2013
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms